3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Phase 1/2
1
Status
Recruiting
2
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Gastrointestinal
49
Tumor-Agnostic
40
Genitourinary
30
Thoracic
29
Breast
29
Head & Neck
25
Gynecologic
21
Dermatologic
13
Sarcoma
12
CNS
9
Other hematologic neoplasm
5
Lymphoid
5
Endocrine
3
NET
2
Myeloid
2
Plasma cell
1
Conditions
Neuroendocrine Tumors
28
Neoplasms
4
Melanoma
4
Carcinoma, Neuroendocrine
4
Sarcoma
3
Pheochromocytoma
3
Pancreatic Neoplasms
3
Ovarian Neoplasms
3
Liver Neoplasms
3
Gastro-enteropancreatic neuroendocrine tumor
3
Colonic Neoplasms
3
Carcinoma, Non-Small-Cell Lung
3
Carcinoma
3
Carcinoid Tumor
3
Breast Neoplasms
3
Thyroid Neoplasms
2
Thymus Neoplasms
2
Stomach Neoplasms
2
Salivary Gland Neoplasms
2
Rectal Neoplasms
2
Prostatic Neoplasms
2
Paraganglioma
2
Neoplasms by Site
2
Neoplasms by Histologic Type
2
Neoplasm Metastasis
2
Multiple Myeloma
2
Meningioma
2
Lung Neoplasms
2
Insulinoma
2
Head and Neck Neoplasms
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Neoplasm Metastasis
×
NET
×
30 days
×
Clear all
NCT07377487
2026-05-22
INDIGO
Boston Scientific Corporation
Phase NA
Recruiting
51 enrolled
NCT07129252
2026-05-11
BRAVESST2
Crinetics Pharmaceuticals Inc.
Phase 1/2
Recruiting
150 enrolled